Reaction Details Report a problem with these data
Target
Prolyl hydroxylase EGLN3
Ligand
BDBM50507409
Substrate
n/a
Meas. Tech.
ChEMBL_1829981 (CHEMBL4329855)
IC50
6.0±n/a nM
Citation
Liu, P; Wang, L; DuBois, BG; Colandrea, VJ; Liu, R; Cai, J; Du, X; Quan, W; Morris, W; Bai, J; Bishwokarma, B; Cheng, M; Piesvaux, J; Ray, K; Alpert, C; Chiu, CS; Zielstorff, M; Metzger, JM; Yang, L; Leung, D; Alleyne, C; Vincent, SH; Pucci, V; Li, X; Crespo, A; Stickens, D; Hale, JJ; Ujjainwalla, F; Sinz, CJ Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia. ACS Med Chem Lett 9:1193-1198 (2018) [PubMed] Article
More Info.:
Target
Name:
Prolyl hydroxylase EGLN3
Synonyms:
EGLN3 | EGLN3_HUMAN | Egl nine homolog 3 (EGLIN3) | Egl nine homolog 3 (EGLN3)
Type:
Protein
Mol. Mass.:
27265.54
Organism:
Human
Description:
Q9H6Z9
Residue:
239
Sequence:
MPLGHIMRLDLEKIALEYIVPCLHEVGFCYLDNFLGEVVGDCVLERVKQLHCTGALRDGQLAGPRAGVSKRHLRGDQITWIGGNEEGCEAISFLLSLIDRLVLYCGSRLGKYYVKERSKAMVACYPGNGTGYVRHVDNPNGDGRCITCIYYLNKNWDAKLHGGILRIFPEGKSFIADVEPIFDRLLFFWSDRRNPHEVQPSYATRYAMTVWYFDAEERAEAKKKFRNLTRKTESALTED